Tevogen Bio Holdingsの空売り状況は、投資家がTevogen Bio Holdingsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Tevogen Bio Holdings (NASDAQ:TVGN) 株価情報, 空売り情報

TEVOGEN BIO HOLDINGS INC

Tevogen Bio Holdings

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Tevogen Bio Holdings Inc

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestorrelations.umb.com%2Foverview%2Fdefault.aspx&amp;esheet=54262038&amp;newsitemid=20250529694925&amp;lan=en-US&amp;anchor=UMB+Financial+Corporation&amp;index=1&amp;md5=90607473541708a7f2fdbff9ed4b853c">UMB Financial Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) announced today the launch of an underwritten public offering of depositary shares (the "depositary shares"), each representing a 1/400th ownership interest in a share of its Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series B, par value $0.01 per share (the "Series B Preferred Stock"), with a liquidation preference of $10,000 per share of Series B Preferred Stock (equivalent to $25 per depositary share). UMB has applied to list the depositary shares on The Nasdaq Global Select Market.
RBC Capital Markets, LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering and Piper Sandler &amp; Co. and Wells Fargo Securities, LLC are acting as co-managers for the offering.
UMB expects to use the net proceeds from the sale of the depositary shares for general corporate purposes, which may include the redemption of all outstanding shares of its 7.00% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series A and the repurchase, redemption, or retirement of a portion of its 3.70% Fixed-to-Fixed Rate Subordinated Notes due 2030.

News

Offerings

UMBF

UMB Financial Launches Public Offering Of Depositary Shares Representing Series B Preferred Stock

As Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) keeps climbing, some public companies aren't just watching from the sidelines &#8211; they're quietly <a href="https://www.benzinga.com/crypto">raking in billions</a> just by holding it.
From household names like Tesla Inc. (NASDAQ: TSLA) and Block Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) to surprise entries like Semler Scientific Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) and Next Technology Holding Inc. (NASDAQ: NXTT), companies that bought Bitcoin early are now enjoying eye-popping gains.
The key? It's not just how much Bitcoin they own &#8211; it's how early and how cheaply they got in.
Let's break down which companies are winning the most from their Bitcoin bets.
<h2 class="wp-block-heading">MicroStrategy: The Ultimate Bitcoin Whale</h2>
No surprises here &#8211; MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) remains the corporate king of Bitcoin. The company holds over 580,000 Bitcoins, and its investment has <a href="https://bitcointreasuries.net/">grown</a> from a $40.6 billion cost to more than $63 billion in value.
That's more than $22 billion in unrealized profit. With over 60% of its market value now tied to Bitcoin, MicroStrategy has become a proxy for crypto exposure on Wall Street.
<h2 class="wp-block-heading">Tesla: Silent Holder, Big Profits</h2>
Elon Musk's Tesla might not talk much about crypto these days, but it certainly knows how to make it count. The EV giant scooped up 11,509 Bitcoins for just $386 million. That same stash is now worth $1.25 billion &#8211; a gain of more than 220%.
For a trillion-dollar company, it's a small position but a massive return.
<h2 class="wp-block-heading">Block: Square's Bitcoin Is Multiplying</h2>
Jack Dorsey's Block, formerly Square, took an early leap into Bitcoin. And it paid off. 
The company's 8,584 Bitcoin holdings have nearly quadrupled in value—from $261 million to over $930 million. While it&#8217;s best known for payments and fintech, Bitcoin is becoming a major part of the story.
Read Also: <a href="https://www.benzinga.com/general/education/25/05/45656079/microsoft-passed-on-bitcoin-while-gamestop-jumped-in-whos-laughing-now">Microsoft Passed On Bitcoin While GameStop Jumped In: Who&#8217;s Laughing Now?</a>
<h2 class="wp-block-heading">GameStop: From Meme To Bitcoin Holder</h2>
GameStop Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) is back in the headlines, this time not for short squeezes but for Bitcoin. The company recently acquired 4,710 Bitcoins, which are now worth over $511 million.
While the purchase price is unknown, the valuation suggests GameStop bought in at an opportune time. With over 3.5% of its market value in Bitcoin, it's the latest unexpected name betting on crypto.
<h2 class="wp-block-heading">Next Technology: A Quiet Crypto Play With Loud Results</h2>
Next Technology might not be a household name, but it's one of the biggest Bitcoin gainers on the list. Its 5,833 Bitcoin investment &#8211; originally worth just $183 million &#8211; is now valued at over $633 million.
That's a gain of more than 240%, making it one of the stealthiest winners in the corporate Bitcoin world.
<h2 class="wp-block-heading">Semler Scientific: From Medical Devices To Digital Gold</h2>
In a move that turned heads, Semler Scientific bought 4,264 Bitcoins worth nearly $463 million. With a market cap of just over $500 million, almost 90% of the company's value is now tied to Bitcoin. It's one of the boldest moves among small-cap companies &#8211; and it could pay off handsomely if Bitcoin keeps rising.
While miners like MARA Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) and Riot Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) have long held Bitcoin as part of their operations, it&#8217;s the companies that bought Bitcoin early and cheaply that are seeing the biggest windfalls. Whether they're tech giants, medical firms, or meme stocks, these Bitcoin believers are proving that timing really is everything.
As corporate treasuries evolve, don't be surprised if more firms follow suit. With returns like these, sitting on Bitcoin might just be the best investment decision they've ever made.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/restaurants/25/05/45660000/steak-n-shake-thanks-bitcoin-for-higher-sales-lower-fees-and-its-celebrating-with-blockchain-menu">Steak &#8216;N Shake Thanks Bitcoin For Higher Sales, Lower Fees — And It&#8217;s Celebrating With &#8216;Blockchain Menu&#8217;</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Long Ideas

Markets

Trading Ideas

$BTC

MARA

MSTR

Next Technology Holding Inc. - Ordinary Shares

NXTT

RIOT

SMLR

TSLA

Tesla, Block Ride Bitcoin Boom As MicroStrategy Goes All In

Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) shares are trading higher, up over 21.5% at the start of the trading <a href="https://www.benzinga.com/movers" target="_blank" rel="noreferrer noopener">session on Thursday.</a>
The retailer reported first-quarter earnings per share loss of 13 cents, beating the <a href="https://www.benzinga.com/pressreleases/25/05/b45665497/kohls-reports-first-quarter-fiscal-2025-financial-results" target="_blank" rel="noreferrer noopener">analyst consensus estimate of 37 cents loss</a>. Quarterly sales of $3.23 billion outpaced the Street view of $3.02 billion.
Net sales decreased by 4.1%, and comparable sales decreased by 3.9% in the quarter under review.
Gross margin&nbsp;as a percentage of net sales was 39.9%, an increase of 37 basis points.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/05/45335453/kohls-dismisses-ceo-over-undisclosed-conflicts-of-interest" rel="noreferrer noopener">Kohl&#8217;s Dismisses CEO Over&#8217; Undisclosed Conflicts Of Interest&#8217;</a>
Operating income&nbsp;was $60 million, higher than $43 million in the prior year. Operating margin was 1.9%, an increase of 58 basis points year-over-year.
Kohl&#8217;s exited the first quarter with cash and equivalents worth $153 million, lower than $228 million in the year-ago period.
Inventory&nbsp;was $3.1 billion, an increase of 2% year-over-year.
The company&#8217;s long-term debt at the end of the quarter stood at $1.174 billion. That&#8217;s lower than $1.638 billion in the year-ago period. 
Outlook: Kohl&#8217;s reaffirmed its FY2025 GAAP EPS outlook of 10 cents to 60 cents vs. the 44 cents estimate and expects a 4%–6% drop in comparable sales.
The company also maintained its sales forecast of $14.31 billion–$14.62 billion.
Kohl&#8217;s expects capital expenditures between $400 million and $425 million for FY2025. It will pay a $0.125 dividend on June 25.
&#8220;Capex of $400 million to $425 million will include investments to complete the Sephora rollout, expand impulse queuing fixtures, and enhance omnichannel experience,&#8221; Kohl&#8217;s Corporation said.
Price Action: KSS shares are trading higher by 6.79% to $8.650&nbsp;premarket at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45667324/wall-streets-most-accurate-analysts-spotlight-on-3-real-estate-stocks-delivering-high-dividend-yields-5" target="_blank" rel="noreferrer noopener">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Real Estate Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

Earnings

Equities

Guidance

Movers

General

Beauty And The Boost: Kohl's Beats Q1 Estimates With Strong Margins; Reiterates Sephora Expansion Plans

Canaccord Genuity analyst George Gianarikas maintains NuScale Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) with a Buy and raises the price target from $26 to $35.

Price Target

Analyst Ratings

Canaccord Genuity Maintains Buy on NuScale Power, Raises Price Target to $35

Build-A-Bear Workshop Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBW#NYSE">BBW</a>) shares surged Thursday after the company posted better-than-expected results for the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45665092/build-a-bear-workshop-reports-record-breaking-first-quarter-fiscal-2025-results" rel="noreferrer noopener">first quarter of fiscal 2025</a>, with revenue rising 11.9% year over year to $128.4 million, surpassing analysts&#8217; expectations of $118.9 million.
The company posted adjusted earnings of $1.17 per share, beating the consensus forecast of <a target="_blank" href="https://www.benzinga.com/quote/BBW/guidance" rel="noreferrer noopener">87 cents</a>.
Net retail sales rose 10.9% to $119.6 million. E-commerce demand edged up 0.5%, while franchise and commercial revenue surged 28.3% to $8.8 million.
Also Read: <a href="https://www.benzinga.com/news/earnings/25/05/45669267/best-buy-whiffs-on-sales-earnings-tariff-pressures-mount">Best Buy Falls Short: Sales, Earnings Miss As Tariff Pressures Mount</a>
Pre-tax income rose 30.6% year over year to $19.6 million, or 15.3% of revenue, driven by higher margins and offset slightly by increased SG&amp;A expenses and lower interest income.
EBITDA rose 26.7% to $23.1 million, representing 18% of total revenue.
Build-A-Bear added 15 global experience locations in the quarter, ending with 604 worldwide. The total includes 369 corporately managed, 148 partner-operated, and 87 franchise locations.
At the end of the first quarter, the company held $44.3 million in cash, up 16% year over year, with no borrowings on its credit facility.
Inventory rose 12.9% to $72.3 million, driven by early purchases of core products. Capital expenditures totaled $2.9 million, compared to $2.4 million a year ago.
Build-A-Bear used $4.2 million to repurchase 108,502 shares and paid a $2.9 million cash dividend. It has $85 million remaining under its $100 million buyback program.
Build-A-Bear reaffirmed its 2025 revenue guidance, projecting mid-single-digit percentage growth. The company now expects pre-tax income between $61 million and $67 million, including current tariff rates.
It continues to anticipate net new unit growth of at least 50 locations, capital expenditures of $20 million to $25 million, and depreciation and amortization of around $16 million.
The guidance reflects current tariffs, labor and medical cost pressures, higher freight costs, and ongoing inflation but does not factor in major changes to tariffs, macroeconomic conditions, or foreign exchange rates.
Price Action: BBW shares are trading higher by 24.3% to $53.16 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45648326/dicks-sporting-goods-profit-falls-short-of-expectations-sticks-to-annual-outlook-despite-tariffs" target="_blank" rel="noreferrer noopener">Dick&#8217;s Sporting Goods Profit Falls Short Of Expectations, Sticks To Annual Outlook Despite Tariffs</a></li>
</ul>
Photo by Ritu Manoj Jethani via Shutterstock

Build-A-Bear Sticks To Outlook Despite Tariff Pressure, Stock Soars 25%

A boba tea and a cookie used to be a small weekly treat. Now, for one worker, it&#8217;s become a financial breaking point.
&#8220;I went and got a cookie and a boba from my favorite shop. After a tip it was $20. That's more than I make in an hour,&#8221; wrote a Reddit user in a post on <a href="https://www.reddit.com/r/povertyfinance/comments/1kta6nt/finally_too_broke_for_boba_and_coffee/">r/povertyfinance</a>. &#8220;I just couldn't stop thinking about how many home-cooked meals that $20 was worth.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
The post titled, &#8220;Finally too broke for boba and coffee,&#8221; quickly resonated, getting over 2,600 upvotes and sparking hundreds of comments from people facing similar budget stress.
<h2 class="wp-block-heading">‘Too Broke For This'</h2>
The poster said they used to get fancy coffee once a week but have now stopped. &#8220;I think I'm going to replace special outing with going to my local Indian grocery store instead. I can make so much curry for $20,&#8221; they wrote. &#8220;Screw this economy.&#8221;
Many in the comments agreed.
&#8220;Every time I&#8217;m about to eat out, I think to myself &#8216;I can make 3 meals at home for this $15,'&#8221; wrote one person. Another added, &#8220;8-10 dollars is like two dinners at home for two people.&#8221;
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
<h2 class="wp-block-heading">The Tip Debate</h2>
While many understood the frustration, some questioned the decision to tip at all.
&#8220;You <a href="https://www.benzinga.com/news/25/01/43236358/tipping-culture-cracking-gratuities-drop-to-a-six-year-low-as-rising-prices-and-overwhelming-gratuity-prompts-turn-customers-away">do not need to tip</a> at counter service food establishments,&#8221; one commenter said. Another added, &#8220;Why are you complaining about the price including the tip, when the tip was you actively choosing to pay extra?&#8221;
But OP stood firm: &#8220;I always tip. I don&#8217;t know if I can't tip for something that's my special treat, it ruins it. Because baristas and retail workers work hard and they do deserve a tip for the low wage in my opinion.&#8221; Their comment got heavily downvoted.
Others pushed back gently, arguing that tipping props up a broken system. &#8220;You&#8217;re unintentionally supporting the tipping culture that allows companies to underpay their employees by passing that cost onto customers,&#8221; one said.
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.
<h2 class="wp-block-heading">Bigger Picture</h2>
What started as a post about boba turned into a broader commentary on the economy. OP summed it up: &#8220;It is hard to justify paying so much for a liquid. It's wild that prices are so high right now, and it looks like they are probably never going down.&#8221;
Some looked even further ahead. One commenter warned, &#8220;Wait until the coming years of this economy&#8230; Check back in 2032. Seven years from now. <a href="https://www.benzinga.com/25/05/45404626/walmart-target-home-depot-ceos-tell-trump-prices-will-rise-shelves-will-be-empty-if-tariffs-persist">Everyday costs of groceries</a>, houses, the stock market will all have doubled again.&#8221;
The mood was captured by another user who simply wrote, &#8220;Buckle in. Only going to get worse.&#8221;
For many, even small pleasures now come with financial guilt. &#8220;We can all be our own barista,&#8221; OP joked in one comment. But behind the humor was a shared frustration: working full time still doesn't make small luxuries like a $20 drink feel affordable.
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

'Screw This Economy'—A Worker Says They're 'Finally Too Broke For Boba And Coffee.' With Tips, It Hit $20—More Than Their Hourly Wage

Goldman Sachs analyst Rajan Sharma reinstates DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Sell and announces $7.25 price target.

Initiation

DBVT

Goldman Sachs Reinstates Sell on DBV Technologies, Announces $7.25 Price Target

Canaccord Genuity analyst Richard Close maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Buy and lowers the price target from $35 to $34.

Canaccord Genuity Maintains Buy on Phreesia, Lowers Price Target to $34

Goldman Sachs analyst Asad Haider initiates coverage on BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Neutral rating and announces Price Target of $110.

BNTX

Goldman Sachs Initiates Coverage On BioNTech with Neutral Rating, Announces Price Target of $110

Canaccord Genuity analyst Susan Anderson maintains e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) with a Buy and raises the price target from $105 to $114.

Canaccord Genuity Maintains Buy on e.l.f. Beauty, Raises Price Target to $114

Goldman Sachs analyst Kash Rangan maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Buy and raises the price target from $340 to $385.

Goldman Sachs Maintains Buy on Salesforce, Raises Price Target to $385

Canaccord Genuity analyst Kingsley Crane maintains C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) with a Hold and lowers the price target from $30 to $28.

Canaccord Genuity Maintains Hold on C3.ai, Lowers Price Target to $28

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/29061750/3sBio-900x600-1.png" alt="" class="wp-image-13563" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/29061750/3sBio-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/29061750/3sBio-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/29061750/3sBio-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The pharma giant Pfizer has bought international rights to the experimental cancer therapy and will take a $100 million equity stake in the Chinese drug developer
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>The mega deal for rights to the Chinese biotech's cancer drug drove 3SBio's stock price to a seven-year high</li>
<li>Big hopes are riding on "dual target" antibody treatments, with Merck &amp; Co. teaming up with another Chinese biopharma on a similar product</li>
</ul>
China's biopharma industry is celebrating a milestone moment after striking a giant licensing deal for one of its experimental cancer treatments.
Multinational drug giant&nbsp;Pfizer&nbsp;(PFE.US) has&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0520/2025052000021.pdf">agreed</a>&nbsp;to hand over an initial $1.25 billion (9 billion yuan) and up to $4.8 billion in milestone payments for international rights to the antibody drug candidate developed by China's&nbsp;3SBio Inc.&nbsp;(1530.HK).
The blockbuster payment marks the Chinese drug sector's biggest overseas licensing deal to date, underscoring its growing role in developing transformative, targeted treatments for a range of cancers, often in partnership with big names in global pharma.
The 3SBio drug under development is a bispecific antibody that targets two protein pathways – PD-1 and VEGF – to fight lung and other cancers.
Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of China. As well as securing record sums in upfront and other fees, the Chinese company stands to get a double-digit percentage of sales in the markets covered by the agreement.
As a further sweetener, Pfizer agreed to take a $100 million equity stake in 3SBio when the deal takes effect later this year, underlining the strategic nature of the relationship.
The news of the bumper deal lit a fire under the Chinese drug developer's stock, which had rallied 13.81% on May 19 and surged another 32.28% the following day to HK$22, its highest level in seven years.
A 3SBiosubsidiary that will get30% of the Pfizer payments,&nbsp;Sunshine Guojian Pharmaceutical (Shanghai)&nbsp;(688336.SH), rose limit-up for four straight days between May 19 and May 22, more than doubling its share price. 3SBio had to rush out a risk statement reminding investors that the deal is still subject to review by the board of directors and approval by U.S. regulators, "subjecting the validity of the licensing agreement to some uncertainties".
The company has been active in China's pharmaceutical industry since 1993, developing several products that have become prominent drugs in their fields. These include treatments for anemia and other blood-related issues including TPIAO, EPIAO and SEPO, and mainland China's first non-prescription product for hair loss, Mandi. The company's revenues rose 16.5% in 2024 to 9.11 billion yuan from the prior year, while net profit jumped 34.9% to 2.09 billion yuan.
SSGJ-707 combines two anti-cancer functions, targeting the PD-1 immune checkpoint to strengthen the body's innate defenses and the VEGF signaling pathway that regulates tumor growth.
Data from Phase Two clinical trials produced promising results on patients suffering from non-small cell lung cancer, both as a standalone treatment and combined with chemotherapy. The drug is also being tested for use against colorectal&nbsp;cancer and gynecological cancers.
<h4 class="wp-block-heading">Dual-action drugs in the spotlight</h4>
In the same category ofPD-1/VEGF treatments, only one bispecific antibody drug has been approved for use so far – ivonescimab from&nbsp;Akeso Biopharma&nbsp;(9926.HK). The drug fared well in a Phase Three trial against the monoclonal antibody Keytruda, an immunotherapy agent from&nbsp;Merck &amp; Co.&nbsp;(MRK.US) that treats lung cancer by targeting the PD-L1 protein. The trial highlighted the potential of PD-1/VEGF bispecific antibodies to strengthen the immune system and attack cancer cells. Back in December 2022, Akeso Biopharma granted exclusive rights to develop and commercialize the drug in the United States, Canada, Europe and Japan to Summit Therapeutics.
Meanwhile Merck has been active in the same arena, gaining rights last November to another PD-1/VEGF candidate, LM-299, from Chinese drug developer LaNova Medicines. The Merck deal grants the Chinese company an upfront sum of $588 million and up to $2.7 billion in milestone payouts, far less than the Pfizer agreement with 3SBio.
Pfizer has been working on its own PD-1/VEGF research for some time. In February this year, Pfizer entered a clinical trial partnership with Summit Therapeutics to explore the combined use of ivonescimab with some of its own antibody drug conjugates to treat solid tumors.
3SBio also teamed up with&nbsp;Sichuan Biokin Pharmaceutical&nbsp;(688506.SH) in February this year for clinical trials on the use of SSGJ-707 combined with an antibody drug conjugate, EGFR/HER3, that targets proteins involved in tumor cell growth. The trial highlighted the potential of drug combinations to combat cancer by multiple means.&nbsp; Having secured the rights to the 3SBio drug, Pfizer may well accelerate clinical trials combining the new asset with its own therapies.
The timing for the push into new cancer therapies is also significant. Wanlian Securities noted in a recent research report that patents on many of Pfizer's blockbuster drugs are approaching their expiry date, prompting the pharma giant to explore the rapidly growing R&amp;D capability in the Chinese biotech industry. Chinese brands could be poised to attract more interest from "Big Pharma", potentially leading to further collaborations and profit-sharing pacts.
3SBio currently trades at a price-to-earnings (P/E) ratio of 21 times, lagging the 49 times for&nbsp;Jiangsu Hengrui Pharmaceuticals&nbsp;(1276.HK; 600276.SH), which is also enjoying success with innovative drugs. The valuation gap suggests some upside potential for 3SBio, if the Pfizer partnership can contribute commercial expertise in launching new drugs as well as a considerable income stream.

Asia

Biotech

Global

Opinion

Pfizer's Mega Deal Highlights China's Rising Role In Global Pharma

JMP Securities analyst Silvan Tuerkcan maintains Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) with a Market Outperform and raises the price target from $5 to $6.

TSHA

JMP Securities Maintains Market Outperform on Taysha Gene Therapies, Raises Price Target to $6

The U.S. economy confirmed signs of fragility in early 2025, as gross domestic product slipped into negative territory, while latest unemployment benefits surged to the highest levels since 2021, suggesting headwinds<a href="https://www.benzinga.com/news/econ-s"> for growth and hiring. </a>
<h3 class="wp-block-heading">GDP Contracts, Corporate Profits Slide</h3>
In the first quarter of 2025, the U.S. gross domestic product shrank at an annualized rate of 0.2%, according to the second estimate by the Bureau of Economic Analysis. While the figure marks a slight upward revision from the initial 0.3% drop reported in April, it remains a sharp slowdown from the 2.4% expansion recorded in the final quarter of 2024.
The downturn was largely driven by a spike in imports, as companies raced to secure goods ahead of Donald Trump&#8216;s trade tariffs—a factor that subtracts from GDP in its calculation. Meanwhile, federal spending declined following cost-cutting mandates by the Department of Government Efficiency, led by Elon Musk.
Consumer spending, the main engine of the U.S. economy, rose just 1.2% on an annualized basis—down from a previously estimated 1.8% and far below the 4% surge in the fourth quarter of 2024. It was the weakest growth in household outlays since the second quarter of 2023.
Corporate earnings also took a hit. Preliminary estimates showed that company profits declined 3.6% quarter-over-quarter to $3.192 trillion. This marked a reversal from a 5.9% gain in the prior quarter and represented the largest drop since the pandemic-era slump in late 2020.
The personal consumption expenditures (PCE) price index—a preferred inflation gauge for the Federal Reserve—rose 3.6% in the first quarter, unchanged from the advance estimate. Core PCE, which excludes volatile food and energy prices, was revised slightly lower to 3.4% from 3.5%, suggesting marginal easing in underlying price pressures.
<h3 class="wp-block-heading">Continuing Jobless Claims Hit Multi-Year High</h3>
Fresh labor market data released Thursday signaled growing strain. Initial jobless claims climbed to 240,000 for the week ending May 10, a 14,000 increase from the previous week and above market expectations of 230,000.
It was the highest weekly print in over a month and the third-largest jump year to date. 
More strikingly, continuing claims—those who remain unemployed and are receiving benefits—rose to 1.919 million in the week ending May 17, up from 1.893 million previously. That marked the highest reading since November 2021.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="535" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29084710/image-388-1024x535.png" alt="" class="wp-image-931539" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29084710/image-388-1024x535.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29084710/image-388-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29084710/image-388-768x401.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29084710/image-388-1536x803.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29084710/image-388-2048x1070.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">Market Reactions</h3>
Markets responded with caution. The U.S. dollar index dropped 0.4% to 99.56, sliding from an overnight high of 100.54.
Futures tied to U.S. equity indices pared overnight gains.
 The S&amp;P 500 dipped 0.1% after the economic data to 5,935, though it remains set to open 0.4% higher thanks in part to Nvidia Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) strong earnings and a court decision to block new tariffs proposed by President Donald Trump.
The Nasdaq 100 slipped slightly from 21,630 to 21,590 but is still poised to open up 0.6%.
Investors will now look to Friday's inflation data and any Fed commentary for further clues on the policy outlook.
Read now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/media/25/05/45664231/teslas-optimus-may-be-the-first-humanoid-robot-to-achieve-high-volume-and-tech-scale-says-nvidia-ceo-jensen-huang-likely-to-be-the-next-multi-trillion-dollar-industry">Tesla&#8217;s Optimus May Be The First Humanoid Robot To Achieve High Volume And Tech Scale, Says Nvidia CEO Jensen Huang: &#8216;&#8230; Likely To Be The Next Multi-Trillion Dollar Industry&#8217; </a></li>
</ul>
Photo: Shutterstock

Government

Macro Economic Events

Regulations

Econ #s

Economics

Tech

NVDA

US Economy Contracts By 0.2% In Q1, Labor Market Shows Signs Of Cracks As Jobless Claims Surge

The collaborative business venture is projected to generate over $5 million in revenue for Jinxin Technology by 2025.
SHANGHAI, May 29, 2025 /PRNewswire/ -- Jinxin Technology Holding Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMI#NASDAQ">NAMI</a>), a leading provider of AI-driven digital content and interactive communication technologies, today announced a major strategic partnership between its flagship platform NamiBox, Tencent Cloud Computing (Beijing) Co., Ltd., and Shenzhen Press Group Publishing House entered into a tripartite strategic partnership. This collaboration marks the official commencement of a new era where AI technology deeply empowers the entire chain of educational publishing. As the core builder of the big data platform for educational publishing, Namibox will assist Shenzhen Press Group Publishing House in launching its &quot;Technology + Culture + Art&quot; brand strategy.
It is understood that the signed project encompasses an&nbsp;AI-assisted textbook&nbsp;compilation system, a virtual teacher course resource library, and an educational publishing big data platform. The aim is to achieve personalized teaching content generation and multi-modal interactive learning experiences through AI technology, driving the transformation of traditional publishing into &quot;smart publishing.&quot; For instance, the AI-assisted system can automatically generate teaching plans tailored to different educational levels based on course syllabi, significantly shortening teachers&#39; lesson preparation time. Meanwhile, virtual teachers can break down geographical barriers to educational resources through multi-lingual and multi-modal interactions.

NAMI

Jinxin Technology, Tencent Cloud And Shenzhen Press Group Enter InTo AI-Powered Educational Publishing Partnership; Collaborative Business Venture Is Projected To Generate Over $5M In Revenue For The Co By 2025

Salesforce Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) reported better-than-expected first-quarter financial results after the <a href="https://www.benzinga.com/quote/crm/earnings">market close on Wednesday.</a>
Salesforce reported first-quarter revenue of $9.83 billion, beating the consensus estimate of $9.75 billion. The company reported first-quarter adjusted earnings of $2.58 per share, beating analyst estimates of $2.55 per share, according to Benzinga Pro.
"We've built a deeply unified enterprise AI platform — with agents, data, apps and a metadata platform — that is unmatched in the industry. With Agentforce, Data Cloud, our Customer 360 apps, Tableau, and Slack all built on one trusted, unified foundation, companies of every size can build a digital labor force — boosting productivity, reducing costs and accelerating growth," said Marc Benioff, chair and CEO of Salesforce.
Salesforce said it expects second-quarter revenue to be in the range of $10.11 billion to $10.16 billion versus estimates of $10.01 billion. The company anticipates second-quarter adjusted earnings of $1.80 to $1.82 per share versus estimates of $1.71 per share.
Salesforce also raised its fiscal-year 2026 revenue guidance to a range of $41 billion to $41.3 billion versus estimates of $40.83 billion. The company raised its full-year adjusted earnings guidance to $7.15 and $7.21 per share versus estimates of $7.24 per share
Salesforce shares fell 0.4% to close at $276.03 on Wednesday.
These analysts made changes to their price targets on Salesforce following earnings announcement.
<ul class="wp-block-list">
<li>RBC Capital analyst Rishi Jaluria downgraded Salesforce from Outperform to Sector Perform and lowered the price target from $420 to $275.</li>
<li>Bernstein analyst Mark Moerdler maintained Salesforce with an Underperform rating and raised the price target from $243 to $255.</li>
</ul>
Considering buying CRM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="594" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29093421/image-392-1024x594.png" alt="" class="wp-image-931626" style="width:535px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29093421/image-392-1024x594.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29093421/image-392-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29093421/image-392-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29093421/image-392.png 1092w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45641430/jim-cramer-says-this-quantum-computing-stock-is-so-high-and-too-speculative">Jim Cramer Says This Quantum Computing Stock Is &#8216;So High&#8217; And &#8216;Too Speculative&#8217;</a> </li>
</ul>
Photo via Shutterstock

These Analysts Revise Their Forecasts On Salesforce Following Q1 Results

Investing in a company before it hits the public markets offers a chance to capture growth early, but it comes with distinct risks and rewards. Many view the IPO as the prime moment to buy shares, yet much of a company's value often builds long before. Nasdaq <a href="https://www.nasdaq.com/articles/as-companies-stay-private-longer-advisors-need-access-to-private-markets">data</a> reveals that firms now spend over a decade in private status, often reaching a $1 billion valuation before going public. This is the domain of pre-IPO investing-a window to tap into rising stars before they shine on the open market.
<h2 class="wp-block-heading">What Defines Pre-IPO Investing?</h2>
Pre-IPO investing involves backing private companies that have outgrown their startup phase but aren't yet listed on exchanges. Unlike IPO shares, which trade freely, pre-IPO stakes are typically illiquid, held until the company goes public or sold in secondary markets. Straddling venture capital and public equities, this stage lets investors buy into businesses showing real momentum at valuations lower than public offerings.
<h2 class="wp-block-heading">Why It Draws Attention</h2>
Pre-IPO opportunities allow investors to secure larger share allocations than in oversubscribed IPOs, where demand often outstrips supply. Early entry can yield significant gains-some companies see their market value surge by 350% within a year of going public. However, the trade-off is clear: private firms offer less transparency, with less rigorous reporting and performance that may vary. For those comfortable with uncertainty, pre-IPO investing provides a shot at outsized returns.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1024" height="768" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/29112848/image-18.png" alt="" class="wp-image-13598" style="width:436px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/29112848/image-18.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/29112848/image-18-300x225.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/29112848/image-18-768x576.png 768w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">Risk Management</h2>
Success in pre-IPO investing hinges on avoiding common pitfalls. Timing and pricing are critical-market volatility or sector slumps can skew valuations unfavorably. Investors need a clear picture of the company's direction: is it a high-growth innovator or a steady cash-flow player? Without a defined roadmap, confidence wanes. Transparency is equally vital; even without public oversight, solid metrics are non-negotiable. We should request detailed cap tables, term sheets, and liquidation preferences to gauge risks like dilution or exit priorities. Finally, companies that treat pre-IPO as a mere funding round rather than a partnership often falter. Open communication builds trust.
<h2 class="wp-block-heading">The Bottom Line</h2>
Pre-IPO investing is more than a high-stakes bet- it's a vital part of today's financial landscape. For those skilled at assessing timing, valuation, and execution, it unlocks value before the broader market catches on. In a world where foresight trumps late moves, disciplined pre-IPO investors can shape tomorrow's success stories.

IPOs

Startups

Pre-IPO Investing: Unlocking Value Before The World Does

Market Summary

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Benzinga Market Summary: Trump Tariffs Struck Down By Federal Court, NVIDIA Rises On Earnings Beat, Tesla Rises As Musk's Government Role Concludes

LOBO EV Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) ("LOBO" or the "Company"), an advanced manufacturer of electric bikes, tricycles, and off-highway four-wheeler electric carts, proudly announced the launch of its second-generation multi-functional robotic platform. Based on a highly modular design, the new platform builds on LOBO's first-generation robotic mower and has been engineered as a versatile base unit capable of transforming into multiple specialized service robots through module customization.

LOBO

LOBO EV Technologies Launches Second-Generation Modular Robotic Platform Designed For Multi-Functionality And Customizable Service Applications

Press Releases

Tevogen Bio Announces 2025 Annual Meeting

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

Small Cap

AI Healthcare Boom Gains Speed as Regulators and Innovators Align

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

Health Care

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow

Comments

Tevogen Bio Holdings

空売り

Tevogen Bio Holdings (NASDAQ:TVGN) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル